Biowaiver for Emusion Dosage Form [Design Issues]

posted by drgunasakaran1  – 2021-05-12 07:52 (168 d 03:45 ago) – Posting: # 22341
Views: 512

» One of our sponsor wants to conduct Bioequivalence study for an Emulsion formulation for intravenous route. Sponsor plans to market the drug as generic version of Innovator in South Africa. But, he enquired whether we can go for biowaiver instead of BE study for Emulsion formulation.

Dear Mr Suraj,

Biowaiver is acceptable for Emulsion provided if fulfills the following requirements as per MCC's Biostudies Guidance.

Quote from Guidance

Emulsions normally do not qualify for a biowaiver.
However, emulsion formulations may be considered eligible for a biowaiver where:

(a) the product is not designed to control release or disposition
(b) the method and rate of administration is the same as the currently approved product


In these cases, the composition should be qualitatively and quantitatively the same as the currently approved emulsion as stated above, and satisfactory data should be provided to demonstrate very similar physicochemical characteristics, including size distribution of the dispersed lipid phase, and supported by other emulsion characteristics considered relevant e.g. surface properties, such as Zeta potential and rheological properties.

Unquote

Reference: https://www.sahpra.org.za/wp-content/uploads/2020/01/61de452d2.06_Biostudies_Jun15_v6.pdf

Dr S Gunasakaran MBBS MD
Disclaimer: The replies/posts are my personal opinions and it does not represent my company views on the same.

Complete thread:

Activity
 Admin contact
21,758 posts in 4,550 threads, 1,545 registered users;
online 7 (0 registered, 7 guests [including 3 identified bots]).
Forum time: Wednesday 11:38 CEST (Europe/Vienna)

There ain’t no rules around here!
We’re trying to accomplish something!    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5